Efficacy of diltiazem administration on the respiratory adverse effects of enalapril Source: Eur Respir J 2002; 20: Suppl. 38, 303s Year: 2002
The effects of multiple dosing of ketoconazole on the pharmacokinetics of a single dose ambrisentan Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008
Once-daily administration of indacaterol does not induce tachyphylaxis in vivo Source: Eur Respir J 2005; 26: Suppl. 49, 216s Year: 2005
No relevant drug-drug interaction between inhaled NVA237 and oral cimetidine Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with asthma Source: Eur Respir J 2007; 30: Suppl. 51, 350s Year: 2007
Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Low systemic exposure of NVA237, an inhaled once-daily anticholinergic bronchodilator, in healthy humans Source: Eur Respir J 2006; 28: Suppl. 50, 661s Year: 2006
Comparison of the pharmacokinetic, pharmacodynamic, and safety profiles of three different formulations of intravenous epoprostenol sodium Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
Lack of cataracts and other localized adverse events in children treated with nebulized budesonide inhalation suspension Source: Eur Respir J 2001; 18: Suppl. 33, 290s Year: 2001
Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
Low systemic exposure to aclidinium bromide, a novel long-acting anticholinergic, after multiple doses Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
Dose escalation study in healthy male subjects to investigate safety, tolerability and systemic exposure of orally inhaled single-doses of AP301 Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012
Efficacy and safety of therapeutic and supratherapeutic doses of indacaterol compared to salmeterol and salbutamol, in mild-to-moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 207s Year: 2006
Aclidinium bromide, a novel long-acting anticholinergic drug, has a good preclinical cardiovascular safety profile Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008
The influencing of respiratory adverse effects of enalapril Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001
Cardiovascular adverse effects during itraconazole therapy Source: Eur Respir J 2008; 32: 240 Year: 2008
The safety of LAMA/LABA combination therapy for the ocular and urinary adverse effects in the COPD patients Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019
Hepatotoxic reactions in rats after administration of component schemes of reserve Anti-TB drugs with different safety profile Source: International Congress 2019 – Tuberculosis: from basic science to patient care Year: 2019
Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF Source: Eur Respir J 2015; 46: 1217-1221 Year: 2015
Long-term safety of medium- and high-dose mometasone furoate/formoterol combination in persistent asthmatics: Analysis of adverse event incidence, plasma cortisol, and ocular changes Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010